Coloplast Beheer

Beheer criteriumcontroles 4/4

De CEO Coloplast is Kristian Villumsen, benoemd in Dec2018, heeft een ambtstermijn van 4.42 jaar. De totale jaarlijkse vergoeding van { bedraagt DKK 21.40M, bestaande uit 54.2% salaris en 45.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.043% van de aandelen van het bedrijf, ter waarde MX$ 213.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 5.3 jaar.

Belangrijke informatie

Kristian Villumsen

Algemeen directeur

DKK 21.4m

Totale compensatie

Percentage CEO-salaris	54.2%
Dienstverband CEO	4.4yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	5.1yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kristian Villumsen's beloning veranderd ten opzichte van Coloplast's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	n/a	n/a	DKK 5b
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b
Jun 30 2017	n/a	n/a	DKK 3b
Mar 31 2017	n/a	n/a	DKK 3b
Dec 31 2016	n/a	n/a	DKK 3b
Sep 30 2016	DKK 10m	DKK 6m	DKK 3b

Compensatie versus markt: De totale vergoeding ($USD 3.11M ) Kristian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 5.78M ).

Compensatie versus inkomsten: De vergoeding van Kristian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kristian Villumsen (52 yo)

4.4yrs

Tenure

DKK 21,400,000

Compensatie

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kristian Villumsen	President & CEO	4.4yrs	DKK 21.40m	0.043% MX$ 213.3m
Anders Lonning-Skovgaard	Executive VP & CFO	8.8yrs	DKK 10.80m	geen gegevens
Allan Rasmussen	Executive Vice President of Global Operations	8.8yrs	DKK 9.60m	0.00015% MX$ 749.3k
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 9.00m	geen gegevens
Paul Marcun	Executive Vice President of Growth	4.3yrs	DKK 11.00m	geen gegevens
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000030% MX$ 149.9k
Ellen Bjurgert	Vice President of Investor Relations	6.6yrs	geen gegevens	geen gegevens
Dennis Kaysen	Director of Corporate Communications	no data	geen gegevens	geen gegevens
Dorthe Ronnau	Senior Vice President of People & Culture	1.3yrs	geen gegevens	geen gegevens
Alain Morvan	Senior Vice President of Sales Europe	11.1yrs	geen gegevens	geen gegevens
Rasmus Møller	Senior Vice President of Wound & Skin Care	2.7yrs	geen gegevens	geen gegevens
Manu Varma	Senior Vice President of Chronic Care - North America	5.1yrs	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0QBO N is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Barfod	Senior Controller & Employees Representative Director	17.3yrs	DKK 450.00k	0.000030% MX$ 149.9k
Carsten Hellmann	Independent Director	5.4yrs	DKK 690.00k	0.0028% MX$ 14.1m
Lars Rasmussen	Chairman of the Board	4.4yrs	DKK 1.84m	0.098% MX$ 487.8m
Niels Louis-Hansen	Deputy Chairman	55.3yrs	DKK 938.00k	21.11% MX$ 105.4b
Marianne Wiinholt	Independent Director	2.4yrs	DKK 880.00k	0.00024% MX$ 1.2m
Jette Nygaard-Andersen	Independent Director	7.4yrs	DKK 600.00k	geen gegevens
Nikolaj Gundersen	Employees Representative Director	5.3yrs	DKK 450.00k	geen gegevens
Roland Pedersen	Employees Representative Director	5.3yrs	DKK 450.00k	0.00070% MX$ 3.5m
Annette Bruls	Independent Director	1.4yrs	DKK 497.00k	geen gegevens

5.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0QBO N wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Coloplast Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Less than half of directors are independent

Less than half of directors are independent

Coloplast Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd